D M Burger

Summary

Affiliation: University Medical Centre Nijmegen
Country: The Netherlands

Publications

  1. ncbi Clinically relevant drug interactions with antiretroviral agents
    D M Burger
    Department of Clinical Pharmacy, University Hospital Nijmegen, The Netherlands
    Antivir Ther 2:149-65. 1997
  2. ncbi Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers
    C J L la Porte
    Department of Clinical Pharmacy, University Medical Centre Nijmegen, Nijmegen University Centre for Infectious Diseases, Nijmegen, The Netherlands
    Antimicrob Agents Chemother 48:1553-60. 2004
  3. ncbi Treatment failure of nelfinavir-containing triple therapy can largely be explained by low nelfinavir plasma concentrations
    David M Burger
    Department of Clinical Pharmacy, University Medical Center, Nijmegen, The Netherlands
    Ther Drug Monit 25:73-80. 2003
  4. ncbi HIV-1 RNA levels in the cerebrospinal fluid may increase owing to damage to the blood-brain barrier
    D M Burger
    Department of Pharmacy, Slotervaart Hospital, Amsterdam, The Netherlands
    Antivir Ther 2:113-7. 1997
  5. ncbi A retrospective, cohort-based survey of patients using twice-daily indinavir + ritonavir combinations: pharmacokinetics, safety, and efficacy
    D M Burger
    Department of Clinical Pharmacy, University Medical Centre Nijmegen, The Netherlands
    J Acquir Immune Defic Syndr 26:218-24. 2001
  6. ncbi Pharmacokinetics of the protease inhibitor indinavir in human immunodeficiency virus type 1-infected children
    D M Burger
    Department of Clinical Pharmacy, University Medical Centre Nijmegen, Nijmegen, The Netherlands
    Antimicrob Agents Chemother 45:701-5. 2001
  7. ncbi Pros and cons of therapeutic drug monitoring of antiretroviral agents
    David M Burger
    Department of Clinical Pharmacy, University Medical Centre Nijmegen, Geert Grooteplein 8, 6525 GA Nijmegen, The Netherlands
    Curr Opin Infect Dis 15:17-22. 2002
  8. ncbi Low plasma concentrations of indinavir are related to virological treatment failure in HIV-1-infected patients on indinavir-containing triple therapy
    D M Burger
    Department of Clinical Pharmacy, University Hospital Nijmegen, The Netherlands
    Antivir Ther 3:215-20. 1998
  9. ncbi The effect of fluconazole on ritonavir and saquinavir pharmacokinetics in HIV-1-infected individuals
    C H Koks
    Department of Pharmacy and Pharmacology, Slotervaart Hospital, Amsterdam, The Netherlands
    Br J Clin Pharmacol 51:631-5. 2001
  10. ncbi Carbamazepine--indinavir interaction causes antiretroviral therapy failure
    P W Hugen
    Department of Clinical Pharmacy, University Hospital Nijmegen, The Netherlands
    Ann Pharmacother 34:465-70. 2000

Detail Information

Publications92

  1. ncbi Clinically relevant drug interactions with antiretroviral agents
    D M Burger
    Department of Clinical Pharmacy, University Hospital Nijmegen, The Netherlands
    Antivir Ther 2:149-65. 1997
    ..It must be emphasized, however, that in many cases these proposals are not backed up by authoritative clinical consensus panels and that clinical experience with many of these combinations is limited...
  2. ncbi Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers
    C J L la Porte
    Department of Clinical Pharmacy, University Medical Centre Nijmegen, Nijmegen University Centre for Infectious Diseases, Nijmegen, The Netherlands
    Antimicrob Agents Chemother 48:1553-60. 2004
    ..5 mg/liter (day 24) and was similar between the two arms. Adjusted-dose regimens of lopinavir-ritonavir in combination with therapeutic drug monitoring and monitoring of liver function may allow concomitant use of rifampin...
  3. ncbi Treatment failure of nelfinavir-containing triple therapy can largely be explained by low nelfinavir plasma concentrations
    David M Burger
    Department of Clinical Pharmacy, University Medical Center, Nijmegen, The Netherlands
    Ther Drug Monit 25:73-80. 2003
    ..014). Virologic failure of nelfinavir-containing triple therapy can be explained, to a large extent, by low plasma levels of nelfinavir...
  4. ncbi HIV-1 RNA levels in the cerebrospinal fluid may increase owing to damage to the blood-brain barrier
    D M Burger
    Department of Pharmacy, Slotervaart Hospital, Amsterdam, The Netherlands
    Antivir Ther 2:113-7. 1997
    ..This study indicates that increased levels of HIV-1 RNA in the CSF of neurologically symptomatic patients are the result of damage to the blood-brain barrier...
  5. ncbi A retrospective, cohort-based survey of patients using twice-daily indinavir + ritonavir combinations: pharmacokinetics, safety, and efficacy
    D M Burger
    Department of Clinical Pharmacy, University Medical Centre Nijmegen, The Netherlands
    J Acquir Immune Defic Syndr 26:218-24. 2001
    ..To describe the pharmacokinetics, safety, and efficacy of twice-daily indinavir + ritonavir regimens..
  6. ncbi Pharmacokinetics of the protease inhibitor indinavir in human immunodeficiency virus type 1-infected children
    D M Burger
    Department of Clinical Pharmacy, University Medical Centre Nijmegen, Nijmegen, The Netherlands
    Antimicrob Agents Chemother 45:701-5. 2001
    ..It would even be better to adjust the indinavir dose based on an AUC of greater than 20 mg/liter. h...
  7. ncbi Pros and cons of therapeutic drug monitoring of antiretroviral agents
    David M Burger
    Department of Clinical Pharmacy, University Medical Centre Nijmegen, Geert Grooteplein 8, 6525 GA Nijmegen, The Netherlands
    Curr Opin Infect Dis 15:17-22. 2002
    ..In addition, therapeutic drug monitoring may be used as a direct and objective instrument to measure non-adherence. This review describes possibilities and limitations of therapeutic drug monitoring in HIV treatment...
  8. ncbi Low plasma concentrations of indinavir are related to virological treatment failure in HIV-1-infected patients on indinavir-containing triple therapy
    D M Burger
    Department of Clinical Pharmacy, University Hospital Nijmegen, The Netherlands
    Antivir Ther 3:215-20. 1998
    ..0) were independent factors related to virological treatment failure. Monitoring of indinavir plasma concentrations may be an important tool for the optimization of triple drug combination therapy...
  9. ncbi The effect of fluconazole on ritonavir and saquinavir pharmacokinetics in HIV-1-infected individuals
    C H Koks
    Department of Pharmacy and Pharmacology, Slotervaart Hospital, Amsterdam, The Netherlands
    Br J Clin Pharmacol 51:631-5. 2001
    ..To study the effect of fluconazole on the steady-state pharmacokinetics of the protease inhibitors ritonavir and saquinavir in HIV-1-infected patients...
  10. ncbi Carbamazepine--indinavir interaction causes antiretroviral therapy failure
    P W Hugen
    Department of Clinical Pharmacy, University Hospital Nijmegen, The Netherlands
    Ann Pharmacother 34:465-70. 2000
    ..To report a case of antiretroviral therapy failure caused by an interaction between carbamazepine and indinavir...
  11. ncbi Simultaneous determination of the HIV-protease inhibitors indinavir, nelfinavir, saquinavir and ritonavir in human plasma by reversed-phase high-performance liquid chromatography
    P W Hugen
    Department of Clinical Pharmacy, University Hospital Nijmegen, The Netherlands
    J Chromatogr B Biomed Sci Appl 727:139-49. 1999
    ..The method was validated extensively and stability tests under various conditions were performed. The assay is now in use to analyse plasma samples from patients treated with (combinations of) HIV-protease inhibitors...
  12. ncbi Durable HIV-1 suppression with indinavir after failing lamivudine-containing double nucleoside therapy: a randomized controlled trial
    N A Foudraine
    Municipal Health Service, Department of Public Health and Environment, Amsterdam, The Netherlands
    Antivir Ther 6:55-62. 2001
    ..To assess CSF concentrations of indinavir at week 48...
  13. ncbi Effect of efavirenz treatment on the pharmacokinetics of nelfinavir boosted by ritonavir in healthy volunteers
    C J L la Porte
    Department of Clinical Pharmacy, University Medical Centre Nijmegen, PO Box 9101, 6500 HB Nijmegen, The Netherlands
    Br J Clin Pharmacol 58:632-40. 2004
    ..In the present study the effect of efavirenz on the pharmacokinetics and tolerability of once-daily nelfinavir/ritonavir was evaluated in healthy subjects...
  14. ncbi Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice
    R M M Cleijsen
    Department of Clinical Pharmacy, Radboud University Medical Centre Nijmegen, The Netherlands
    J Antimicrob Chemother 60:897-900. 2007
    ..Therapeutic drug monitoring (TDM) is being applied for a number of antiretroviral agents. Little is known about the use of TDM for atazanavir...
  15. ncbi Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8, and nevirapine in human plasma by reversed-phase high-performance liquid chromatography
    J A H Droste
    Deparment of Clinical Pharmacy, University Medical Center Nijmegen, Nijmegen, The Netherlands
    Ther Drug Monit 25:393-9. 2003
    ..This method proved to be simple, accurate, and precise and is useful for the therapeutic drug monitoring of protease inhibitors and the nonnucleoside reverse transcriptase inhibitor nevirapine on a routine basis...
  16. ncbi Dose-finding study of a once-daily indinavir/ritonavir regimen
    P W Hugen
    Department of Clinical Pharmacy Department of General Internal Medicine, University Medical Centre St Radboud Nijmegen and National AIDS Therapy Evaluation Centre, Academical Medical Centre, Amsterdam, The Netherlands
    J Acquir Immune Defic Syndr 25:236-45. 2000
    ..Steady-state pharmacokinetic data of once-daily IDV/RTV regimens in HIV-infected patients are warranted...
  17. ncbi Simultaneous determination of the HIV nucleoside analogue reverse transcriptase inhibitors lamivudine, didanosine, stavudine, zidovudine and abacavir in human plasma by reversed phase high performance liquid chromatography
    C P W G M Verweij-van Wissen
    Department of Clinical Pharmacy, University Medical Centre Nijmegen, P O Box 9101, 6500 HB Nijmegen, The Netherlands
    J Chromatogr B Analyt Technol Biomed Life Sci 816:121-9. 2005
    ..5% and extraction recoveries were higher than 97%. This method proved to be simple, accurate and precise, and is currently in use in our laboratory for the quantitative analysis of NRTIs in plasma...
  18. ncbi Age-dependent pharmacokinetics of lamivudine in HIV-infected children
    D M Burger
    Department of Clinical Pharmacy, Radboud University Medical Centre, Nijmegen, The Netherlands
    Clin Pharmacol Ther 81:517-20. 2007
    ..In conclusion, further investigation of the relationship between decreased lamivudine exposure and treatment outcome and long-term resistance development in younger children with HIV infection is warranted...
  19. ncbi Pharmacokinetics of indinavir combined with low-dose ritonavir in human immunodeficiency virus type 1-infected children
    A S Bergshoeff
    University Medical Center, Department of Clinical Pharmacy, Nijmegen University Center for Infectious Diseases, Nijmegen, The Netherlands
    Antimicrob Agents Chemother 48:1904-7. 2004
    ..1 (0.87 to 1.3), 0.96 (0.60 to 1.5), and 0.80 (0.68 to 0.94), respectively...
  20. ncbi Pharmacokinetic study of tenofovir disoproxil fumarate combined with rifampin in healthy volunteers
    J A H Droste
    Department of Clinical Pharmacy, University Medical Centre Nijmegen, P O Box 9101, 533 KF, 6500 HB Nijmegen, The Netherlands
    Antimicrob Agents Chemother 49:680-4. 2005
    ..In conclusion, adaptation of either the rifampin or the tenofovir DF dose for the simultaneous treatment of tuberculosis and human immunodeficiency virus (HIV) infection in HIV-infected patients is probably not required...
  21. ncbi Development of an indinavir oral liquid for children
    P W Hugen
    Department of Clinical Pharmacy, Faculty of Medicine, University Hospital Nijmegen, Netherlands
    Am J Health Syst Pharm 57:1332-9. 2000
    ..An oral liquid formulation of indinavir was developed that had an acceptable taste, was chemically stable, and was bioequivalent to the commercially available capsule...
  22. ncbi Effect of rifampin on steady-state pharmacokinetics of atazanavir with ritonavir in healthy volunteers
    D M Burger
    Department of Clinical Pharmacy, Radboud University Medical Center, Nijmegen, The Netherlands
    Antimicrob Agents Chemother 50:3336-42. 2006
    ..Coadministration of ATV with RIF was safe and generally well tolerated. Since ATV exposures were reduced in all regimens, ATV and RIF should not be coadministered at the dosing regimens studied...
  23. ncbi Pharmacokinetics, food intake requirements and tolerability of once-daily combinations of nelfinavir and low-dose ritonavir in healthy volunteers
    R E Aarnoutse
    Department of Clinical Pharmacy, University Medical Centre Nijmegen, Nijmegen, The Netherlands
    Br J Clin Pharmacol 55:115-25. 2003
    ..This study was performed to evaluate the steady-state pharmacokinetics, food intake requirements and short-term tolerability of once-daily combinations of nelfinavir and low-dose ritonavir...
  24. ncbi Pharmacokinetics of two generic co-formulations of lopinavir/ritonavir for HIV-infected children: a pilot study of paediatric Lopimune versus the branded product in healthy adult volunteers
    C T M M de Kanter
    Clinical Pharmacy, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    J Antimicrob Chemother 65:538-42. 2010
    ....
  25. ncbi The effect of atazanavir and atazanavir/ritonavir on UDP-glucuronosyltransferase using lamotrigine as a phenotypic probe
    D M Burger
    Department of Clinical Pharmacy, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Clin Pharmacol Ther 84:698-703. 2008
    ..45 for lamotrigine to 0.71 for ATV/RTV + lamotrigine. ATV alone does not significantly influence glucuronidation of lamotrigine. In contrast, ATV/RTV results in moderately decreased exposure to lamotrigine...
  26. ncbi Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis
    H M J Nijland
    Department of Clinical Pharmacy, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Clin Infect Dis 45:1001-7. 2007
    ..Rifampicin induces the phase II metabolic enzymes that are involved in the biotransformation of moxifloxacin. Therefore, the interaction between rifampicin and moxifloxacin should be investigated...
  27. ncbi High-performance liquid chromatography of HIV protease inhibitors in human biological matrices
    R E Aarnoutse
    Department of Clinical Pharmacy, University Medical Center Nijmegen, The Netherlands
    J Chromatogr B Biomed Sci Appl 764:363-84. 2001
    ..Participation in an interlaboratory quality control program is recommended for every laboratory engaged in the bioanalysis of PIs...
  28. ncbi Simultaneous determination of the azoles voriconazole, posaconazole, isavuconazole, itraconazole and its metabolite hydroxy-itraconazole in human plasma by reversed phase ultra-performance liquid chromatography with ultraviolet detection
    C P W G M Verweij van Wissen
    Department of Clinical Pharmacy, Radboud University Nijmegen Medical Centre, P O Box 9101, 6500 HB Nijmegen, The Netherlands
    J Chromatogr B Analyt Technol Biomed Life Sci 887:79-84. 2012
    ..This method proved to be simple, accurate, precise and fast and is currently in use in our laboratory for the quantitative analysis of these azoles for Therapeutic Drug Monitoring and pharmacokinetic research...
  29. ncbi Antiretroviral therapy in HIV patients: aspects of metabolic complications and mitochondrial toxicity
    H J M ter Hofstede
    Department of Internal Medicine, University Hospital Nijmegen, PO Box 9101, 6500 HB Nijmegen, The Netherlands
    Neth J Med 61:393-403. 2003
  30. ncbi Saquinavir soft-gel capsules (Fortovase) give lower exposure than expected, even after a high-fat breakfast
    P W H Hugen
    Department of Clinical Pharmacy, University Medical Centre Nijmegen, 533 Dept Clinical Pharmacy, 6500 HB Nijmegen, The Netherlands
    Pharm World Sci 24:83-6. 2002
    ..However, in a Dutch study population using saquinavir-sgc plasma levels were lower than expected. We hypothesised that this was caused by differences in the amount of fat in the meals of the study populations...
  31. ncbi The effect of cholecalciferol supplementation on vitamin D levels and insulin sensitivity is dose related in vitamin D-deficient HIV-1-infected patients
    C J P van den Bout-van den Beukel
    Departments of General Internal Medicine, Radbound University Nijmegen Medical Center, Nijmegen, The Netherlands
    HIV Med 9:771-9. 2008
    ..The aim of this study was to explore the effects of cholecalciferol supplementation on vitamin D levels, bone mineral density (BMD), body fat distribution and insulin sensitivity in vitamin D-deficient HIV-1-infected patients...
  32. ncbi A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer
    I M E Desar
    Department of Medical Oncology 452, Radboud University Nijmegen Medical Centre, PO Box 9101, Nijmegen, 6500 HB, The Netherlands
    Br J Cancer 103:1637-43. 2010
    ..The combination of sorafenib (vascular endothelial growth factor receptor 2 inhibitor) and sirolimus (mammalian target of rapamycin inhibitor) might work synergistically...
  33. ncbi Results of 2 years of treatment with protease-inhibitor--containing antiretroviral therapy in dutch children infected with human immunodeficiency virus type 1
    Annemarie M C van Rossum
    Department of Pediatrics, Sophia Children's Hospital, 3015 GJ Rotterdam, The Netherlands
    Clin Infect Dis 34:1008-16. 2002
    ..In a high percentage of the children, clinical, virologic, and immunologic response rates to combination therapy were optimal during the initial 2 years of therapy...
  34. ncbi Nevirapine concentrations in HIV-infected children treated with divided fixed-dose combination antiretroviral tablets in Malawi and Zambia
    Jane C Ellis
    Department of Paediatrics, College of Medicine, Blantyre, Malawi
    Antivir Ther 12:253-60. 2007
    ..To investigate nevirapine concentrations in African HIV-infected children receiving divided Triomune tablets (stavudine+lamivudine+nevirapine)...
  35. ncbi No virological failure in semen during properly suppressive antiretroviral therapy despite subtherapeutic local drug concentrations
    Selwyn H Lowe
    Department of Internal Medicine, Division of Infectious Diseases, Tropical Medicine and AIDS, Academic Medical Centre, University of Amsterdam, Amsterdam
    HIV Clin Trials 7:285-90. 2006
    ..The aim of the study was to investigate whether drug resistance occurs earlier in seminal than in blood plasma with the use of such HAART regimens, of which only the two NRTIs achieve therapeutic concentrations in seminal plasma...
  36. ncbi Pharmacokinetics of two generic fixed-dose combinations for HIV-infected children (Pedimune Baby & Pedimune Junior) are similar to the branded products in healthy adults
    Rafaëlla F A L'homme
    Department of Clinical Pharmacy, Radboud University Medical Centre, Nijmegen, The Netherlands
    J Antimicrob Chemother 59:92-6. 2007
    ..We determined the pharmacokinetic profiles of stavudine, lamivudine and nevirapine in Pedimune and compared these with the branded products...
  37. ncbi Assessment of adherence to HIV protease inhibitors: comparison and combination of various methods, including MEMS (electronic monitoring), patient and nurse report, and therapeutic drug monitoring
    Patricia W H Hugen
    Department of Clinical Pharmacy, University Medical Centre Nijmegen, The Netherlands
    J Acquir Immune Defic Syndr 30:324-34. 2002
    ..Adherence to protease inhibitor-containing antiretroviral therapy is crucial, but difficult to measure...
  38. ncbi A randomized controlled trial of genotypic HIV drug resistance testing in HIV-1-infected children: the PERA (PENTA 8) trial
    Hannah Green
    MRC Clinical Trials Unit, London, UK
    Antivir Ther 11:857-67. 2006
    ..To evaluate the longer-term utility of genotypic resistance testing in HIV-1-infected children with virological failure...
  39. ncbi Evaluation of antiretroviral therapy results in a resource-poor setting in Blantyre, Malawi
    Joep J van Oosterhout
    Department of Medicine, College of Medicine, University of Malawi, Blantyre, Malawi
    Trop Med Int Health 10:464-70. 2005
    ..The only ART was a fixed drug combination of stavudine, lamivudine and nevirapine...
  40. ncbi Lopinavir/ritonavir reduces lamotrigine plasma concentrations in healthy subjects
    Manon J van der Lee
    Department of Clinical Pharmacy, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Clin Pharmacol Ther 80:159-68. 2006
    ..Limited data are available about the effect of lopinavir and low-dose ritonavir on glucuronidation. Lamotrigine undergoes glucuronidation. We studied the effect of lopinavir/ritonavir on the pharmacokinetics of lamotrigine and vice versa...
  41. ncbi Adherence and acceptability of once daily Lamivudine and abacavir in human immunodeficiency virus type-1 infected children
    Marthe LePrevost
    Family Clinic, North West London NHS Trust, London, United Kingdom
    Pediatr Infect Dis J 25:533-7. 2006
    ..CONCLUSION: Adherence to once daily abacavir/lamivudine was good with no evidence of an association between nonadherence and virologic rebound. Acceptability of once daily drugs was best when the whole regimen was dosed once daily...
  42. ncbi Boosted versus unboosted indinavir with zidovudine and lamivudine in nucleoside pre-treated patients: a randomized, open-label trial with 112 weeks of follow-up (HIV-NAT 005)
    Mark A Boyd
    The HIV Netherlands Australia Thailand Research Collaboration, The Thai Red Cross AIDS Research Center, Bangkok, Thailand
    Antivir Ther 11:223-32. 2006
    ..The use of HIV protease inhibitors (PIs) in a ritonavir (RTV)-boosted form is now common. However, randomized data comparing boosted with unboosted PI strategies are scarce...
  43. ncbi False-positive results in urine drug screening in healthy volunteers participating in phase 1 studies with efavirenz and rifampin
    Charles J L la Porte
    Ther Drug Monit 28:286. 2006
  44. ncbi Maintenance of successful ritonavir-boosted indinavir and efavirenz therapy in an HIV-infected patient with tuberculosis
    Mark A Boyd
    AIDS 20:1083-5. 2006
  45. ncbi Ketoconazole is inferior to ritonavir as an alternative booster for saquinavir in a once daily regimen in Thai HIV-1 infected patients
    Reshma Saskia Autar
    HIV Netherlands Australia Thailand Research Collaboration HIV NAT, Thai Red Cross Aids Research Centre TRCARC, 104 Rajdumri Road, 10330 Pathumwan, Bangkok, Thailand
    AIDS 21:1535-9. 2007
    ..However, toxicity, storage conditions and high costs of antiretroviral treatment may necessitate interruption of ritonavir. Ketoconazole was investigated as a potential booster of once-daily (o.d.) saquinavir...
  46. ncbi Plasma concentrations of the HIV-protease inhibitor lopinavir are suboptimal in children aged 2 years and below
    Gwenda Verweel
    Erasmus MC Sophia Children s Hospital, Rotterdam, The Netherlands
    Antivir Ther 12:453-8. 2007
    ..We studied LPV pharmacokinetics to determine whether the recommended dose (230/57.5 mg/m2 twice daily) results in optimal LPV exposure in all age groups. Virological efficacy was a secondary objective...
  47. ncbi A retrospective TDM database analysis of interpatient variability in the pharmacokinetics of lopinavir in HIV-infected adults
    Martijn R van der Leur
    Department of Clinical Pharmacy, Radboud University Medical Center Nijmegen, The Netherlands
    Ther Drug Monit 28:650-3. 2006
    ....
  48. ncbi The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers
    Rob E Aarnoutse
    Department of Clinical Pharmacy, University Medical Centre, Nijmegen, The Netherlands
    Clin Pharmacol Ther 71:57-67. 2002
    ....
  49. ncbi International interlaboratory quality control program for measurement of antiretroviral drugs in plasma
    Rob E Aarnoutse
    Department of Clinical Pharmacy, University Medical Centre Nijmegen, Nijmegen, The Netherlands
    Antimicrob Agents Chemother 46:884-6. 2002
    ..The results demonstrate the need for and utility of an ongoing quality control program in this area of bioanalysis...
  50. ncbi High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir/ritonavir tablets
    Hanneke M J Nijland
    Department of Clinical Pharmacy, Radboud University Nijmegen Medical Centre, The Netherlands
    AIDS 22:931-5. 2008
    ..Our objective was to study the combined use of rifampicin and the newly introduced lopinavir/ritonavir tablets...
  51. ncbi Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected children
    Tim R Cressey
    Institut de Recherche pour le Developpement, Program for HIV Prevention and Treatment, UR 174, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand
    Clin Infect Dis 46:1601-8. 2008
    ....
  52. ncbi Nevirapine, stavudine and lamivudine pharmacokinetics in African children on paediatric fixed-dose combination tablets
    Rafaëlla F A L'homme
    Department of Clinical Pharmacy, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    AIDS 22:557-65. 2008
    ..We determined whether this ratio results in optimal exposure in the target population...
  53. ncbi Relationships between drug exposure, changes in metabolic parameters and body fat in HIV-infected patients switched to a nucleoside sparing regimen
    Reshma S Autar
    The HIV Netherlands Australia Thailand Research Collaboration Thai Red Cross AIDS Research Center, Bangkok, Thailand
    Antivir Ther 12:1265-71. 2007
    ..The pathogenesis of metabolic disturbances in treated HIV infection is incompletely understood...
  54. ncbi Assessing self-reported adherence to HIV therapy by questionnaire: the SERAD (Self-Reported Adherence) Study
    Jose A Muñoz-Moreno
    Lluita contra la SIDA Foundation, Badalona, Barcelona, Catalonia, Spain
    AIDS Res Hum Retroviruses 23:1166-75. 2007
    ....
  55. ncbi Semen quality and drug concentrations in seminal plasma of patients using a didanosine or didanosine plus tenofovir containing antiretroviral regimen
    Selwyn H Lowe
    Department of Internal Medicine, Division of Infectious Diseases, Tropical Medicine and AIDS, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Ther Drug Monit 29:566-70. 2007
    ..The authors conclude that ddI and TFV penetrate well into seminal plasma and that the reduced sperm motility deserves further study...
  56. ncbi Plasma levels of zidovudine twice daily compared with three times daily in six HIV-1-infected children
    Alina S Bergshoeff
    Department of Clinical Pharmacy, University Medical Center, 6500 HB Nijmegen, The Netherlands
    J Antimicrob Chemother 54:1152-4. 2004
    ..0. CONCLUSIONS: The plasma pharmacokinetic parameters of zidovudine taken every 8 h and every 12 h were not significantly different and therefore suggest bioequivalence of these two dose frequencies...
  57. ncbi Interaction study of the combined use of paroxetine and fosamprenavir-ritonavir in healthy subjects
    Manon J van der Lee
    Department of Clinical Pharmacy, Radboud University Medical Centre Nijmegen, Geert Grooteplein 10, 6525 GA Nijmegen, The Netherlands
    Antimicrob Agents Chemother 51:4098-104. 2007
    ..This is partly explained by protein displacement of paroxetine. We think that this interaction is clinically relevant and that titration to a higher dose of paroxetine may be necessary to accomplish the needed antidepressant effect...
  58. ncbi Long-term suppression of viral replication despite low plasma saquinavir concentrations in the CHEESE Study
    Rolf P G van Heeswijk
    Br J Clin Pharmacol 53:211-2. 2002
  59. ncbi Nevirapine-based antiretroviral therapy started early in the course of tuberculosis treatment in adult Malawians
    Joep J G van Oosterhout
    University of Malawi College of Medicine, Department of Medicine, Malawi
    Antivir Ther 12:515-21. 2007
    ..Starting antiretroviral therapy early during tuberculosis treatment may improve outcome but problems often arise with drug interactions, adherence, toxicity and immune reconstitution disease (IRD)...
  60. ncbi The genotypic inhibitory quotient and the (cumulative) number of mutations predict the response to lopinavir therapy
    Jolanda G M Hoefnagel
    Department of Medical Microbiology, Nijmegen University Centre for Infectious Diseases, The Netherlands
    AIDS 20:1069-71. 2006
    ..Furthermore, the predictive value of the GIQ was no different from that of the number of mutations alone...
  61. ncbi The use of pharmacokinetically guided indinavir dose reductions in the management of indinavir-associated renal toxicity
    Mark A Boyd
    HIV Netherlands Australia Thailand Research Collaboration, The Thai Red Cross AIDS Research Centre Bangkok, Thailand
    J Antimicrob Chemother 57:1161-7. 2006
    ..We prospectively studied the use of therapeutic drug monitoring in patients with virological success but established nephrotoxicity on an indinavir-containing regimen...
  62. ncbi Role of the inhibitory quotient in HIV therapy
    Jolando G M Hoefnagel
    Department of Medical Microbiology, Radboud University Nijmegen Medical Centre, The Netherlands
    Antivir Ther 10:879-92. 2005
    ..As the IQ can be modified by adjustment of the drug dosage, it may be of clinical value. Its application in patient care should therefore be further investigated...
  63. ncbi Therapeutic drug monitoring in children with HIV/AIDS
    Pieter L A Fraaij
    Department of Pediatrics, Erasmus MC-Sophia, Rotterdam, The Netherlands
    Ther Drug Monit 26:122-6. 2004
    ..We conclude that TDM is a useful tool in the treatment of HIV-1-infected children. Additional data are needed to establish child-specific reference values and to assess the optimal method of TDM...
  64. ncbi Safety and efficacy of a NRTI-sparing HAART regimen of efavirenz and lopinavir/ritonavir in HIV-1-infected children
    Pieter L A Fraaij
    Department of Pediatrics, Erasmus MC-Sophia, Rotterdam, The Netherlands
    Antivir Ther 9:297-9. 2004
    ..Observed side effects were transient with the exception of dyslipidaemia...
  65. ncbi Comparison of two reduced-dose regimens of indinavir (600 mg vs 400 mg twice daily) and ritonavir (100 mg twice daily) in healthy volunteers (COREDIR)
    Jan Christian Wasmuth
    Department of Internal Medicine I, University of Bonn, Germany
    Antivir Ther 9:213-20. 2004
    ..To assess the pharmacokinetics and tolerability of reduced dosages of twice daily indinavir (IDV) boosted by low-dose ritonavir (RTV) in healthy volunteers...
  66. ncbi Evaluation of antiretroviral drug measurements by an interlaboratory quality control program
    Jacqueline A H Droste
    Department of Clinical Pharmacy, University Medical Center, Nijmegen, The Netherlands
    J Acquir Immune Defic Syndr 32:287-91. 2003
    ..This variability may have important implications for therapeutic drug monitoring of these drugs and for pharmacokinetic studies. Interlaboratory testing is useful to alert laboratories to previously undetected analytical problems...
  67. ncbi Ritonavir-enhanced pharmacokinetics of nelfinavir/M8 during rifampin use
    Alina S Bergshoeff
    Department of Clinical Pharmacy, University Medical Center, Nijmegen, The Netherlands
    Ann Pharmacother 37:521-5. 2003
    ..To describe a case of successful protease inhibitor-based highly active antiretroviral therapy (HAART) concomitant with rifampin...
  68. ncbi Pharmacokinetics of indinavir/ritonavir (800/100 mg twice a day) combined with efavirenz in HIV-infected patients
    Rob E Aarnoutse
    Department of Clinical Pharmacy, University Medical Centre Nijmegen, Nijmegen, The Netherlands
    AIDS 18:565-7. 2004
    ..The pharmacokinetic data suggest that indinavir/ritonavir plus efavirenz (without dose modifications) should be effective in treatment-naive patients, and this was supported by the treatment response of the participants...
  69. ncbi Therapeutic drug monitoring: an aid to optimising response to antiretroviral drugs?
    Rob E Aarnoutse
    Department of Clinical Pharmacy, University Medical Center Nijmegen, Nijmegen, The Netherlands
    Drugs 63:741-53. 2003
    ..Additional clinical trials are needed before routine TDM can be adopted as standard of care in the treatment of HIV infection...
  70. ncbi The effect of nevirapine on the pharmacokinetics of indinavir/ritonavir 800/100 mg BID
    David M Burger
    J Acquir Immune Defic Syndr 35:97-8. 2004
  71. ncbi A once-daily HAART regimen containing indinavir + ritonavir plus one or two nucleoside reverse transcriptase inhibitors (PIPO study)
    David M Burger
    Department of Clinical Pharmacy, University Medical Center Nijmegen, The Netherlands
    Antivir Ther 8:455-61. 2003
    ..A Phase II study was conducted to investigate the pharmacokinetics, and short-term safety and efficacy of an indinavir/ritonavir combination as part of a once-daily regimen...
  72. ncbi Pharmacokinetics of indinavir/ritonavir (800/100 mg) in combination with efavirenz (600 mg) in HIV-1-infected subjects
    Mark A Boyd
    The HIV Netherlands Australia Thailand Research Collaboration, The Thai Red Cross AIDS Research Centre, Bangkok, Thailand
    J Acquir Immune Defic Syndr 34:134-9. 2003
    ....
  73. ncbi Administration of indinavir and low-dose ritonavir (800/100 mg twice daily) with food reduces nephrotoxic peak plasma levels of indinavir
    Rob E Aarnoutse
    Department of Clinical Pharmacy, University Medical Centre Nijmegen, The Netherlands
    Antivir Ther 8:309-14. 2003
    ..High indinavir Cmax values have been associated with indinavir-related nephrotoxicity...
  74. ncbi Pharmacokinetics of nelfinavir in children: influencing factors and dose implications
    Alina S Bergshoeff
    University Medical Centre, Department of Clinical Pharmacy, Nijmegen, The Netherlands
    Antivir Ther 8:215-22. 2003
    ..The study describes the pharmacokinetics (PK) of the protease inhibitor nelfinavir and its active metabolite M8 in children and evaluates the influence of patient-related factors on nelfinavir plasma levels...
  75. ncbi Lopinavir/ritonavir plus saquinavir in salvage therapy; pharmacokinetics, tolerability and efficacy
    Charles J L la Porte
    Department of Clinical Pharmacy, University Medical Centre, Nijmegen, The Netherlands
    AIDS 17:1700-2. 2003
    ..The tolerability of the regimen was good and efficacy was encouraging...
  76. ncbi Maintaining the nelfinavir trough concentration above 0.8 mg/L improves virologic response in HIV-1-infected children
    David M Burger
    University Medical Centre Nijmegen, Nijmegen University Centre for Infectious Diseases, Geert Grooteplein 8, 6525 GA Nijmegen, The Netherlands
    J Pediatr 145:403-5. 2004
    ..8 mg/L. Virologic response at week 48 was observed in 29% of children with subtherapeutic nelfinavir troughs versus 80% in children with therapeutic nelfinavir troughs (P=.02)...
  77. ncbi Nelfinavir plasma concentrations are low during pregnancy
    Jeannine F J B Nellen
    Academic Medical Center, Department of Internal Medicine, Division of Infectious Diseases, Tropical Medicine, and AIDS, Amsterdam, The Netherlands
    Clin Infect Dis 39:736-40. 2004
    ..After we adjusted for confounders, we found that the mean nelfinavir CR was 34% lower in pregnant women (P=.02). With targeted interventions, subsequent CRs in pregnant women showed a significant increase (median increase, 0.31; P=.01)...
  78. ncbi Therapeutic drug monitoring of nelfinavir in pregnancy: a case report
    David M Burger
    Department of Clinical Pharmacy, University Medical Center, Nijmegen, The Netherlands
    Ther Drug Monit 26:576-8. 2004
    ..Although a causal relationship cannot be proven, viral load became undetectable after our interventions. A healthy uninfected daughter was born...
  79. ncbi Assessment of drug-drug interactions between tenofovir disoproxil fumarate and the nonnucleoside reverse transcriptase inhibitors nevirapine and efavirenz in HIV-infected patients
    Jacqueline A H Droste
    Department of Clinical Pharmacy, Radboud University, Nijmegen Medical Centre, The Netherlands
    J Acquir Immune Defic Syndr 41:37-43. 2006
    ..Furthermore, the combination of efavirenz 600 mg and tenofovir DF 300 mg once daily was compared with use of efavirenz 600 mg once daily only...
  80. ncbi Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers
    Rob E Aarnoutse
    Departments of Clinical Pharmacy and General Internal Medicine, Nijmegen University Centre for Infectious Diseases, Radboud University Nijmegen Medical Centre, 6500 HB Nijmegen, The Netherlands
    Clin Pharmacol Ther 78:664-74. 2005
    ..When applied in a therapeutic dose (600 mg twice daily), ritonavir also inhibits CYP2D6. The effect of low-dose ritonavir on CYP2D6 is unknown and was investigated in this study...
  81. ncbi Interindividual variability of once-daily ritonavir boosted saquinavir pharmacokinetics in Thai and UK patients
    Reshma Saskia Autar
    The HIV Netherlands Australia Thailand Research Collaboration, Thai Red Cross AIDS Research Centre, Bangkok, 104 Rajdumri Road, 10330 Pathumwan, Bangkok, Thailand
    J Antimicrob Chemother 56:908-13. 2005
    ..Differential exposure to saquinavir/ritonavir may lead to therapy failure. The objective was to identify factors that influence variability of saquinavir/ritonavir plasma concentrations...
  82. ncbi TDM: therapeutic drug measuring or therapeutic drug monitoring?
    Jacqueline A H Droste
    Department of Clinical Pharmacy, University Medical Centre, Nijmegen, The Netherlands
    Ther Drug Monit 27:412-6. 2005
    ..Almost half of the recommendations (44%) given were satisfactory. Levels of knowledge regarding HIV treatment appeared to be variable among the respondents and for this reason were partly incomparable...
  83. ncbi The pharmacology of antiretroviral nucleoside and nucleotide reverse transcriptase inhibitors: implications for once-daily dosing
    David J Back
    Department of Pharmacology, University of Liverpool, Liverpool, UK
    J Acquir Immune Defic Syndr 39:S1-23, quiz S24-25. 2005
    ....
  84. ncbi Pharmacokinetics of once-daily lopinavir/ritonavir and the influence of dose modifications
    Charles J L la Porte
    Department of Clinical Pharmacy, Radboud University Medical Centre, Nijmegen, The Netherlands
    AIDS 19:1105-7. 2005
    ..Dose modifications in four patients with Ctrough levels less than 1.0 mg/l succeeded in only one patient. Therapeutic drug monitoring can identify patients with lower-than-expected lopinavir exposure in a larger study...
  85. ncbi Increased dose of lopinavir/ritonavir compensates for efavirenz-induced drug-drug interaction in HIV-1-infected children
    Alina S Bergshoeff
    Department of Clinical Pharmacy, University Medical Center, 6500 HB Nijmegen, The Netherlands
    J Acquir Immune Defic Syndr 39:63-8. 2005
    ..CONCLUSION: The increased dose of 300/75 mg/m2 twice-daily lopinavir/ritonavir compensates for the enzyme-inducing effect of efavirenz in HIV-infected children...
  86. ncbi Sustained viral suppression and immune recovery in HIV type 1-infected children after 4 years of highly active antiretroviral therapy
    Pieter L A Fraaij
    Department of Pediatrics, Erasmus Medical Center-Sophia Children's Hospital, Rotterdam, The Netherlands
    Clin Infect Dis 40:604-8. 2005
    ..A high proportion of the children had undetectable HIV-1 RNA levels. CD4+ T cell counts recovered and remained stable. Adverse events were observed frequently but were mostly mild...
  87. ncbi Persistent sterile leukocyturia is associated with impaired renal function in human immunodeficiency virus type 1-infected children treated with indinavir
    Annemarie M C van Rossum
    Department of Pediatrics, Sophia Children's Hospital/Erasmus University Medical Centre Rotterdam, Rotterdam, The Netherlands
    Pediatrics 110:e19. 2002
    ..Indinavir-associated nephrotoxicity must be monitored closely, especially in children with risk factors such as persistent sterile leukocyturia, age <5.6 years, an area under the curve of indinavir >19 mg/L x h, and a C(max) >12 mg/L...
  88. ncbi Therapeutic drug monitoring of indinavir and nelfinavir to assess adherence to therapy in human immunodeficiency virus-infected children
    Annemarie M van Rossum
    Department of Pediatrics, Sophia Children's Hospital/Erasmus University Medical Center, Rotterdam, The Netherlands
    Pediatr Infect Dis J 21:743-7. 2002
    ..02, respectively). CONCLUSION: Calculation of adherence rates using the lower limit of CORALs of indinavir or nelfinavir in children may be a useful measurement for the assessment of nonadherence to antiretroviral therapy in children...
  89. ncbi Pharmacokinetic variability caused by gender: do women have higher indinavir exposure than men?
    David M Burger
    J Acquir Immune Defic Syndr 29:101-2. 2002
  90. ncbi Persistent leukocyturia and loss of renal function in a prospectively monitored cohort of HIV-infected patients treated with indinavir
    Jeanne P Dieleman
    Pharmacoepidemiology Unit, and Department of Internal Medicine, Erasmus Medical Centre, Rotterdam, The Netherlands
    J Acquir Immune Defic Syndr 32:135-42. 2003
    ..The data show that leukocyturia is a frequent finding and emphasize the need for monitoring renal function during indinavir treatment, even in the absence of urologic symptoms...
  91. ncbi Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load
    Juan A Arnaiz
    Hospital Clinic-IDIBAPS, University of Barcelona, Spain
    AIDS 17:831-40. 2003
    ..However, the IDV q8h arm performed better when discontinuations were classified as failures. IDV/RTV q12h can be convenient and equally effective for patients able to tolerate it...
  92. ncbi Brief report: enzyme inducers reduce elimination half-life after a single dose of nevirapine in healthy women
    Rafaëlla F A L'homme
    Department of Clinical Pharmacy, Radboud University Medical Centre, Nijmegen, The Netherlands
    J Acquir Immune Defic Syndr 43:193-6. 2006
    ..The objective of this study was to find enzyme inducers to reduce the NVP half-life...